It revealed a well circumscribed, midline placed, hyperdense lesion in posterior fossa, without hydrocephalous [ Figure 1 ]. All features were suggestive of acute intracerebellar bleeding. He was advised to consult a neurosurgeon. Because of his stable condition, parents differed. One and half month after this incidence, he again developed insidious onset of occipital headache and nuchal stiffness, followed by intermittent vomiting and unsteadiness of gait. He had history of bleeding disorder in his family. One of his brothers had already expired in early childhood, because of excessive bleeding from an external wound. On examination, we found bilateral papilloedema, truncal ataxia ansd nuchal stiffness. Magnetic resonance imaging of brain revealed mid-posterior cerebellar, sub-acute, intracerebellar bleed, extending down towards foramen of Magnum. There was associated mass effect, compressing the 4 th ventricle and causing tri ventricular dilatation . His coagulation profile was suggestive of moderately severe hemophilia (Raised Activated Partial Thromboplastin Time and factor VIII assay -3% of normal factor). He was managed conservatively with six units of fresh frozen plasma transfusion and intravenous tranexamic acid. He improved clinically, and was discharged with oral tranexamic acid preparation, 3 times daily for next 10 days. Parents and the child were explained the reason for the disease and the child was advised to avoid outdoor and sports activities, where there is risk of accidental injury. On follow-up after 1 and ½ month, the child was fine and attending school regularly. Hematoma had spontaneously resolved as seen in the repeat CT scan [ Figure 6 ].
Introduction
Hemophilia is one of the oldest described genetic diseases. It is the most common X-linked genetic disease and the second most common factor deficiency after von Willebrand disease. [1] It has been further classified into A, B and C depending upon deficient clotting factor (VIII, IX and XI), respectively. Hemophilia A makes up approximately 80% of all hemophilia cases. The worldwide incidence of hemophilia A is approximately 1 case per 5000 male individuals. Because hemophilia is an X-linked recessive condition, it occurs predominantly in males. Females usually are asymptomatic carriers.
Case Report
A 12-year-old boy from rural area sustained head injury due to fall from height of 2 m while playing, 2 months back. He had history of transient loss of consciousness and vomiting, without history of convulsion or ear nose and throat bleeding. Computed tomography (CT) scan was done after 24 h of trauma. Persons with 1-3% normal factor are considered to have moderately severe hemophilia and more than 3% but <30% normal factor are considered to have mild hemophilia. [2] Factor VIII supplementation is the cornerstone to arrest bleeding in hemophilia cases. Fresh frozen plasma, cryoprecipitate and factor VIII concentrates are rich in factor VIII. [2, 3] Among the above products factor VIII concentrates are the best, as it rapidly corrects the levels. Fibrinolysis inhibitors like tranexamic acid and epsilon aminocaproic acid further enhance clot formation by inhibiting clot lysis. As these patients require frequent factor replacement, making them prone to AIDS and viral hepatitis. With improved screening of donors, new methods of factor concentrate purification, and recombinant concentrates, infectious complications had decreased significantly.
Intracranial hemorrhage and hemorrhages into the soft tissue around vital areas, such as the airway or internal organs, remain the most important life-threatening complications. [4] In children sports injury is the major cause of intracranial bleed. Early detection and prompt correction of factor level prevents devastating complications. There are few case reports of successful intracranial surgery in hemophilia patients available in literature. [4] This was possible because of the availability of clotting factor replacement therapy. The recommended factor level desired before proceeding for intracranial surgery is 80-100% and this level has to be maintained for 14 post-operative days. These clotting factor are expensive. In developing countries many such patients are not able to afford them. In developed countries much importance has been given to prophylactic recombinant product therapy. A cost-benefit analysis indicates that this approach reduces overall factor use and significantly reduces morbidity. Factor concentrates have made home-replacement therapy possible, improving patients' quality of life.
Conclusion
With appropriate education and treatment, patients with hemophilia can live full and productive lives. Choosing safe sports is vital for children with hemophilia. In case of traumatic intracranial bleed, prompt diagnosis and conservative approach through procoagulant transfusion and intravenous fibrinolysis inhibitors should be tried as first line of management. Before daring for surgery sufficient amount of factor replacement should be kept available.
